CHARLOTTE, N.C.--(BUSINESS WIRE)--European private equity firm Cinven today announced that it has agreed to sell AMCo (‘the Group’), the niche specialty pharmaceuticals group to TSX/Nasdaq-listed Concordia Healthcare Corporation, (‘Concordia’ or ‘the Company’), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, for an enterprise value of $3.5 billion, through a combination of cash, shares, and a performance-based earnout. “On the back of their extensive knowledge and first-hand experience of transacting in the pharma space, Bourne Partners were able to help provide significant guidance as we prepared for our exit process” Bourne Partners, a leading healthcare and consumer healthcare investment banking, merchant banking, and investment firm, acted as a financial advisor to Cinven and AMCo on the transaction. “We were pleased to offer our unique market knowledge and industry relationships to aid AMCo in generating this very positive outcome for Cinven as well as Concordia,” said Banks Bourne, Chief Executive Officer and Senior Managing... More